Webb22 feb. 2024 · Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on … WebbProtalix BioTherapeutics, Inc. (PLX) Stock Price, News, Quote & History - Yahoo Finance Dow 30 33,485.29 (+0.01%) Nasdaq 12,087.96 +91.09(+0.76%) Russell 2000 1,754.46 +2.33(+0.13%) Crude Oil... Discover historical prices for PLX stock on Yahoo Finance. View daily, weekly or … Find the latest Protalix BioTherapeutics, Inc. (PLX) stock discussion in Yahoo … Find the latest Protalix BioTherapeutics, Inc. (PLX) stock quote, history, news and … See the company profile for Protalix BioTherapeutics, Inc. (PLX) including … See Protalix BioTherapeutics, Inc. (PLX) stock analyst estimates, including … Find out the direct holders, institutional holders and mutual fund holders for … View the basic PLX option chain and compare options of Protalix … See Protalix BioTherapeutics, Inc. (PLX) Environment, Social and Governance …
ProtalixBioTherapeutics, Inc. $60,000,0004.50% Convertible Notes ...
Webb3 jan. 2024 · Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange PRNewswire 4:30 PM -- December 5, 2024 -- Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed … WebbProtalix BioTherapeutics Inc. (PLX) Stock Price Today, News, Quotes, FAQs and Fundamentals DIA 0.44% 0.15% QQQ HKD 16.59% SNOW 6.11% RIOT 13.04% PYPL … hip pain at night while resting
Stock Information Investor Relations Protalix BioTherapeutics
Webb12 apr. 2024 · Protalix Biotherapeutics Inc (PLX) stock is higher by 6.17% while the S&P 500 has fallen -0.09% as of 11:05 AM on Wednesday, Apr 12. PLX has risen $0.14 from the previous closing price of $2.35 on volume of 1,981,573 shares. Webb12 apr. 2024 · Protalix Biotherapeutics Inc (PLX) stock is higher by 6.17% while the S&P 500 has fallen -0.09% as of 11:05 AM on Wednesday, Apr 12. PLX has risen $0.14 from … Webb24 sep. 2024 · About Protalix Biotherapeutics' Clinical Programs in Fabry Disease The BALANCE Study is a 24-month, randomized, double blind, active control study of PRX‑102 (pegunigalsidase alfa) in Fabry ... hip pain arthritis or bursitis